Are you making sure your GLPs are made in a US 797 compliant lab?

August 21, 2025

In the world of pharmaceutical compounding, ensuring compliance with the latest standards is crucial for safety and quality. USP General Chapter <797> outlines specific requirements for compounded sterile preparations (CSPs) to minimize risks of contamination and harm to patients. As of November 1, 2023, new revisions to the guidelines became enforceable, demanding heightened attention and adjustment to laboratory practices. This article explores the key facets of USP 797 compliance, offering insights into environmental monitoring, training, and operational standards that laboratories must uphold.

What USP 797 Compliance Entails

What is USP <797> compliance?

USP <797> compliance refers to the regulations governing sterile drug compounding in pharmacies to ensure patient safety. This involves performing sterile compounding within an ISO 5 (Class 100) laminar flow hood, which should ideally be situated in a cleanroom maintaining an ISO 7 (Class 10,000) Buffer Zone.

Sterile compounding is classified into three risk categories—Low, Medium, and High—each requiring specific compliance measures:

  • Low Risk : Involves simple manipulations, requiring basic precautions.
  • Medium Risk : Involves more complex compounding activities, necessitating stricter adherence to protocols.
  • High Risk : Involves highly complex processes with significant contaminant exposure, demanding the highest level of compliance.

Proper design is essential, with cleanrooms made from materials like Fiberglass Reinforced Plastic (FRP) and High-Pressure Laminate (HPL) , facilitating a controlled environment that minimizes contamination.

Additionally, compliance with USP <797> aligns with Current Good Manufacturing Practices (CGMP), including ongoing air quality and cleanliness monitoring crucial to safe drug preparation.

Accessing USP 797 Guidelines

How to access USP <797>?

To access USP General Chapter <797>, visit the USP Compounding Compendium website, as the transition to an online platform occurred on November 1, 2023. The chapter is no longer available in PDF format, reflecting updated practices in healthcare safety standards.

Educational resources for USP 797

The compendium also provides valuable educational resources, including FAQs and commentary to help professionals navigate the revised standards effectively. Staying abreast of these updates is crucial for ensuring compliance and maintaining patient safety during sterile compounding.

Importance of staying informed on guidelines

Staying informed about USP <797> changes is vital due to its considerable impact on patient safety in compounding practices. Regularly checking for updates through the compendium can assist personnel in adhering to best practices and mitigating contamination risks.

Application of USP 797 in Physician Offices

Relevance of USP 797 for Physician Offices

Yes, USP <797> applies to physician offices that engage in sterile compounding. This regulation is designed to ensure the safe preparation and handling of sterile medications, aiming to minimize contamination and errors. Any healthcare facility, including physician offices, that prepares sterile products must follow these guidelines to maintain patient safety and ensure proper compounding practices.

Ensuring Safe Preparation in Healthcare Settings

Compliance with USP <797> is crucial in all settings where sterile preparations are made, including physician offices. The handling and administration of medications, such as lenograstim, require adherence to stringent protocols. Effective practices like routine surface testing, personnel sampling, and environmental monitoring are essential to safeguard the sterility of compounded products.

Protocols for Maintaining Compliance

Physician offices must implement thorough training for staff on proper garbing and compounding techniques. Daily cleaning procedures and regular assessments of the cleanroom conditions help to align with USP <797>. Moreover, embracing web-based systems for training and documentation can enhance compliance efforts and streamline processes in these healthcare environments.

Designing a USP 797 Compliant IV Compounding Room

What are the USP <797> compliant room requirements for IV compounding?

To achieve compliance with USP <797>, the IV compounding room must maintain at least ISO Class 7 air quality. This involves having a positive air pressure differential of a minimum of 0.01 inch water column in relation to adjacent areas. Such measures help to prevent contamination from the surrounding environment.

The room should be equipped with a HEPA filtration system that effectively captures airborne particles as small as 0.3 microns. Smooth and non-porous surfaces are essential for easy cleaning and disinfection, preventing debris accumulation that could harbor microorganisms.

It's also important for the IV room to feature a hand hygiene sink with touch-free faucets and designated storage areas for sterile and non-sterile supplies. This setup promotes efficient hygiene practices and organization within the compounding space.

Regular environmental monitoring is crucial. This includes air and surface sampling and continuous monitoring of pressure differentials between classified areas to address any potential risks quickly.

Personnel training and hygiene protocols

Personnel working in the IV room must undergo rigorous training in aseptic techniques. This includes understanding the protocols for garbing, cleaning, and monitoring their hygiene practices. Initial competency testing is required, which can involve observational assessments to ensure adherence to guidelines.

Additionally, glove fingertip sampling is mandatory. Staff must demonstrate effective hand hygiene, with benchmarks in place for the acceptable level of microbial contamination. Routine training updates and competency evaluations are essential to maintain compliance and ensure patient safety in sterile compounding environments.

Training and Testing for USP 797 Compliance

How important is ongoing training in maintaining USP 797 compliance?

Routine personnel training is crucial for maintaining compliance with USP 797 standards. It serves as a preventative measure against human error, which is a common risk factor in sterile environments. Training programs should include initial evaluations and periodic re-assessments of staff on essential topics such as:

  • Aseptic techniques
  • Gowning procedures
  • Contamination prevention measures

Employees must understand specific tasks in their roles and demonstrate high competency in maintaining sterile conditions. Regular glove fingertip sampling and environmental monitoring through air and surface assessments are also required, ideally taking place every six months to maintain stringent compliance.

Why is environmental testing critical under USP 797 guidelines?

Environmental testing is vital under USP 797 as it identifies potential microbial contamination sources, safeguarding the sterility of compound preparations. Cleanroom environments must undergo routine checks, which include:

  • Air sampling
  • Surface sampling
  • Glove fingertip testing

These assessments must yield results showing less than 3 CFU (Colony-Forming Units) to demonstrate adherence to safety standards. By continuously monitoring environmental conditions, compounding pharmacies can effectively manage contamination risks, ensuring the safety of pharmaceuticals produced.

Ensuring Compliance with Revised USP 797 Guidelines

What are the major changes in the revised USP 797 guidelines?

The revised USP 797 guidelines, effective November 1, 2023, introduce significant changes aimed at enhancing the safety and quality of compounded sterile preparations (CSPs). Among these changes:

  • Increased Environmental Monitoring : There's now a requirement for more frequent environmental monitoring, particularly in cleanroom environments.
  • Microbial Identification : Facilities must identify microorganisms to the genus level, highlighting the importance of understanding contamination risks.
  • Updated Cleanroom Standards : Revisions to cleanroom requirements will also affect the protocols followed by compounding personnel.

These changes underscore the necessity for compounding pharmacies to review and update their standard operating procedures (SOPs) accordingly, ensuring all staff members are adequately trained on the new compliance standards. Non-compliance will be closely monitored by state pharmacy boards, which can impose penalties for violations.

How do these changes impact laboratory operations?

The updates to the USP 797 guidelines necessitate substantial changes across laboratory workflows. Operations are affected in numerous ways:

  • Training and Competency : Regular training sessions for the compounding staff must be increased to familiarize them with the new procedures, which could require additional time and resources.
  • Workflow Optimization : Facilities have the chance to enhance their operations beyond mere compliance. This includes improving safety measures and operational efficiencies.

These adjustments are essential for ensuring compliance and safeguarding patient care. A proactive approach to these revisions will benefit laboratories in maintaining high standards of safety and quality.

Ensuring Safety and Compliance in Sterile Compounding

Adhering to USP 797 standards is no longer optional but an essential component in ensuring the safety and efficacy of compounded sterile preparations. Laboratories that prioritize and consistently practice these compliance measures not only safeguard patient health but also fortify their operational credibility. With the full enforcement of the updated guidelines, it becomes ever more imperative to integrate these standards into daily compounding practices, fostering a culture of vigilance and excellence in pharmaceutical compounding.

References

Dialysis center staff coordinating phosphate binder supply with a pharmacy partner
August 11, 2026
What dialysis centers should look for in a phosphate binder supply partner: reliable delivery, formulary breadth, insurance support, and coordination.
Renal dietitian reviewing phosphate levels with a dialysis patient
August 11, 2026
How hyperphosphatemia is managed in ESRD dialysis patients, diet, dialysis, and phosphate binders, and why reliable binder supply keeps therapy on track.
July 29, 2026
Compounded medications are a routine part of modern care, but unlike mass-manufactured drugs, each one is prepared individually, which means the standards behind its preparation carry real weight. For providers who order or refer for compounded therapies, a working understanding of those standards is the clearest way to judge whether a pharmacy is safe to trust. This overview covers the standards that govern sterile compounding and what they mean for the medications your patients receive. Why Standards Matter More in Compounding A commercially manufactured drug is produced under FDA oversight in large, validated batches. A compounded medication is prepared for an individual patient, often in small quantities, sometimes because no commercial equivalent exists. That flexibility is exactly why it's clinically valuable — and why the standards around preparation exist. Without rigorous controls, the same customization that helps patients could introduce contamination or error. Our guide to our sterile compounding pharmacy describes how those controls come together in practice. The Regulatory Landscape Sterile compounding sits within a layered framework: The United States Pharmacopeia (USP) publishes the general chapters, most importantly <797> and <800>, that define how compounded preparations should be made and handled. State boards of pharmacy license and inspect pharmacies, including where they're permitted to ship. Multi-state operations must maintain licensure in each state they serve. Accreditation bodies (ACHC, NABP, PCAB) provide independent verification that a pharmacy meets recognized standards. Together, these create the accountability structure behind every compounded dose. USP <797>: Sterile Preparations USP <797> is the cornerstone standard for compounded sterile preparations. It governs the conditions and practices required to keep a preparation free of contamination, including personnel training and garbing, ISO-classified air quality and engineering controls, environmental monitoring, and beyond-use dating. For any medication infused directly into the body, <797> compliance is the baseline expectation, not a premium feature. USP <800>: Hazardous Drugs USP <800> adds a containment layer for hazardous drugs, protecting personnel, patients, and the environment from unintended exposure. It specifies containment engineering controls, PPE, and validated handling procedures for drugs identified as hazardous. When a preparation is both sterile and hazardous, it must satisfy <797> and <800> together. For the details, see our breakdown of USP <800> requirements . Accreditation: Independent Verification Standards are only meaningful if someone checks that they're being met. Accreditation from ACHC, NABP, and PCAB means a pharmacy has been inspected against national benchmarks by an outside authority. For a provider, accreditation is a shortcut to confidence: it signals that the pharmacy's claims about its processes have been independently validated. The Quality-Control Process Behind the standards is a repeatable process that governs each preparation: Pharmacist review of the prescription for appropriateness, compatibility, and dosing Preparation by trained technicians under aseptic conditions In-process and final verification by a licensed pharmacist Sterility testing or filtration validation where required This chain is what turns a standard on paper into a safe medication in a patient's hands. What This Means When You Order When you refer a patient for a compounded therapy, you're effectively extending your own standard of care into another facility. Knowing that a pharmacy is USP-compliant, accredited, and pharmacist-led lets you refer with confidence that the medication will meet the same expectations you'd hold for anything you administer yourself. If you're weighing options, our guide on how to choose a compounding partner walks through the criteria. The Pharmko Standard Pharmko compounds every TPN, IDPN, and IPN preparation in a USP <797>-compliant, ISO Class 5 cleanroom, under ACHC, NABP, and PCAB accreditation, with a licensed pharmacist reviewing and releasing each formula. For the patients who receive our preparations, many of them managing End Stage Renal Disease (ESRD), that standard is the point. Refer a Patient → · [1 (877) 540-2003]
Physician evaluating a sterile compounding pharmacy partner
July 29, 2026
How to evaluate a sterile compounding pharmacy: accreditation, USP compliance, clinical support, turnaround, and the questions every practice should ask.
Sterile compounding pharmacy technician in PPE under a containment hood
July 29, 2026
A clear guide to USP 800 requirements: hazardous drug handling, containment, PPE, and the facility standards every sterile compounding pharmacy must meet.
Myasthenia Gravis and IVIG: What Patients Need to Know About IV Therapy
July 20, 2026
Learn how IVIG therapy works for myasthenia gravis, when it's used, what to expect during infusions, how home IVIG is coordinated, and how Pharmko supports MG patients and their neurologists.
Dobutamine and Inotrope Therapy at Home
July 17, 2026
Learn how home dobutamine infusion works for advanced heart failure, who qualifies, how continuous inotrope therapy is managed at home, and how Pharmko supports cardiac patients and heart failure teams.
CIDP and Home Infusion: IVIG Treatment, Dosing Schedule, and Long-Term Management
July 16, 2026
Learn how IVIG therapy works for CIDP, what the dosing schedule looks like, how to transition to home infusion, and how Pharmko supports long-term CIDP management across 22+ states.
Compounded IV Medications
July 15, 2026
Most medications that patients receive at a hospital or pharmacy come in standardized, commercially manufactured forms, a 500mg antibiotic vial, a pre-filled syringe, a fixed-concentration IV bag. These products work well for many patients. But a significant portion of patients receiving IV therapy have clinical needs that commercial products cannot meet: a dose the manufacturer doesn't make, a formulation incompatible with the patient's allergy profile, or a combination of nutrients that must be tailored to individual lab values. For these patients, compounded IV medications are not optional, they are clinically necessary. Pharmko's sterile compounding services prepare customized IV medications for patients across 22+ states, with every formulation reviewed by a licensed pharmacist and prepared in a USP <797> compliant cleanroom. What Makes an IV Medication 'Compounded'? A compounded medication is one that is prepared specifically for an individual patient by a licensed pharmacist, rather than manufactured in bulk by a pharmaceutical company. Compounding involves combining, mixing, or altering ingredients, active pharmaceutical ingredients, diluents, preservatives, to create a final preparation that meets the patient's unique prescription requirements. For IV therapy specifically, compounding means preparing a sterile preparation, one that is completely free of viable microorganisms and safe to inject or infuse directly into the bloodstream. This requires specialized facilities, equipment, training, and quality systems that go far beyond what a standard retail pharmacy can provide. Pharmko is exclusively a sterile compounding pharmacy. We do not compound oral medications, topical creams, or non-sterile preparations. Every product we make is intended for intravenous, intraperitoneal, or subcutaneous administration. When Are Compounded IV Medications Necessary? The required dose doesn't exist commercially Pharmaceutical manufacturers produce medications in standardized strengths and volumes based on average patient needs. Pediatric patients, patients with renal or hepatic impairment requiring dose adjustments, or patients whose weight or clinical status falls outside standard ranges may need concentrations or volumes that no commercial product provides. Compounding fills this gap precisely. The patient has an allergy to a commercial formulation's inactive ingredients Commercial IV products often contain preservatives, stabilizers, or diluents, sulfites, benzyl alcohol, certain dyes, that some patients cannot tolerate. A compounding pharmacy can prepare an equivalent formulation without the offending ingredient, allowing the patient to receive the therapy safely. The medication requires individualized nutrient formulation Total parenteral nutrition (TPN) is the clearest example: every TPN formula must be individually compounded because no commercial product can provide the precise combination of amino acids, dextrose, lipids, electrolytes, vitamins, and trace minerals a specific patient needs. The formula changes as the patient's labs, weight, and clinical status change, making standardization impossible. The commercial product is unavailable or in shortage Drug shortages are a persistent reality in the US pharmaceutical supply chain. When a commercially manufactured IV medication becomes unavailable, compounding pharmacies can often prepare an equivalent formulation from available active pharmaceutical ingredients, bridging the gap and maintaining continuity of therapy for patients who cannot wait. The therapy requires a custom delivery format Some IV medications require specific pH, osmolarity, or concentration adjustments for compatibility with a patient's IV access device or concurrent medications. A compounding pharmacist reviews compatibility and prepares formulations that are safe and stable for the specific administration route and equipment the patient is using. How Compounded IV Medications Are Made Step 1: Prescription review Every compounded IV medication begins with a valid prescription from a licensed prescriber. Pharmko's pharmacists review the prescription for clinical appropriateness, dosing accuracy, ingredient compatibility, and stability before compounding begins. Step 2: Ingredient sourcing and verification Active pharmaceutical ingredients for compounding must come from FDA-registered suppliers and meet USP monograph specifications. Each lot is verified for identity, potency, and purity before use. Step 3: Sterile preparation in a controlled environment Preparation occurs in an ISO Class 5 laminar airflow workbench or biological safety cabinet, located within a buffer room that meets ISO Class 7 air quality standards. Pharmacy technicians follow validated, written procedures for each preparation type, using aseptic technique to prevent contamination at every step. Step 4: Pharmacist verification and release A licensed pharmacist performs a final check of every preparation, verifying appearance, volume, labeling, and documentation, before the product is released. High-risk or complex preparations may undergo sterility testing with defined beyond-use dates based on test results. Step 5: Cold-chain delivery Most compounded IV medications require refrigeration. Pharmko uses validated cold-chain packaging and delivery logistics to ensure products arrive within their stability windows and remain temperature-controlled until the patient uses them. Quality Standards That Matter Not all compounding pharmacies operate at the same standard. The relevant quality benchmarks for sterile compounding are: USP <797> compliance, the national standard for sterile compounding environments, personnel, and processes. Our guide on USP <797> and USP <800> explains what compliance means in practice ACHC accreditation, independent third-party verification that Pharmko meets clinical quality standards for home infusion and sterile compounding State pharmacy board licensure, Pharmko is licensed in every state where we serve patients Environmental and personnel monitoring, documented air and surface sampling, personnel gowning competency assessments, and media fill testing at defined intervals For a foundational overview of what sterile compounding is and how it differs from retail pharmacy, see our guide on what is sterile compounding for IV therapy . → Contact Pharmko about compounded IV medications: 1-877-540-2003
home infusion therapy Pennsylvania
July 14, 2026
Pharmko provides home infusion therapy across Pennsylvania, IV antibiotics, IVIG, TPN, biologics, and specialty medications. Licensed, ACHC accredited, and available 24/7 statewide.
Show More